Suppr超能文献

沙美特罗/丙酸氟替卡松与丙酸氟替卡松对轻度持续性哮喘成年患者气道生理影响的比较。

Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma.

作者信息

Houghton Catherine M, Lawson Naomi, Borrill Zoe L, Wixon Claire L, Yoxall Sally, Langley Stephen J, Woodcock Ashley, Singh Dave

机构信息

North West Lung Research Centre, South Manchester University Hospitals Trust, Manchester, UK.

出版信息

Respir Res. 2007 Jul 14;8(1):52. doi: 10.1186/1465-9921-8-52.

Abstract

BACKGROUND

This study compared the effect of inhaled fluticasone propionate (FP) with the combination of salmeterol/fluticasone propionate (SFC) on lung function parameters in patients with mild asthma.

METHODS

Adult patients with mild persistent asthma (> or = 80% predicted FEV1) receiving 200-500 mug of BDP or equivalent were randomised to receive either FP 100 mug or SFC 50/100 mug twice daily from a Diskus inhaler for four weeks. The primary outcome was the change from baseline in airway resistance (sRaw) at 12 hrs post dose measured by whole body plethysmography. Impulse oscillometry and spirometry were also performed.

RESULTS

A comparison of the geometric mean sRaw at 12 hrs post dose in the SFC group to the FP group gave a ratio of 0.76 (0.66 - 0.89, p < 0.001) at week 2 and 0.81 (0.71 - 0.94, p = 0.006) at week 4. Similarly, significant results in favour of SFC for oscillometry measurements of resistance and reactance were observed. FEV1 was also significantly superior at week 2 in the SFC group (mean difference 0.16L, 95% CI; 0.03 - 0.28, p = 0.015), but not at week 4 (mean difference 0.17L, 95% CI -0.01 - 0.34, p = 0.060).

CONCLUSION

SFC is superior to FP in reducing airway resistance in mild asthmatics with near normal FEV1 values. This study provides evidence that changes in pulmonary function in patients with mild asthma are detected more sensitively by plethysmography compared to spirometry

TRIAL REGISTRATION NUMBER

NCT00370591.

摘要

背景

本研究比较了吸入丙酸氟替卡松(FP)与沙美特罗/丙酸氟替卡松(SFC)联合用药对轻度哮喘患者肺功能参数的影响。

方法

成年轻度持续性哮喘患者(FEV1预计值≥80%),接受200 - 500微克倍氯米松二丙酸酯或等效药物治疗,随机分为两组,分别使用Diskus吸入器每日两次吸入100微克FP或50/100微克SFC,为期四周。主要观察指标是用药后12小时通过全身体积描记法测量的气道阻力(sRaw)相对于基线的变化。同时也进行了脉冲振荡法和肺量计检查。

结果

SFC组与FP组用药后12小时的几何平均sRaw比较,第2周时比值为0.76(0.66 - 0.89,p < 0.001),第4周时为0.81(0.71 - 0.94,p = 0.006)。同样,在脉冲振荡法测量阻力和电抗方面,也观察到显著有利于SFC的结果。SFC组在第2周时FEV1也显著更高(平均差值0.16升,95%置信区间;0.03 - 0.28,p = 0.015),但在第4周时并非如此(平均差值0.17升,95%置信区间 -0.01 - 0.34,p = 0.060)。

结论

对于FEV1值接近正常的轻度哮喘患者,SFC在降低气道阻力方面优于FP。本研究提供了证据表明,与肺量计检查相比,体积描记法能更敏感地检测出轻度哮喘患者的肺功能变化。

试验注册号

NCT00370591。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8534/1971055/c168071b9e4c/1465-9921-8-52-1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验